Clinical Trial Update: A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma [Phase 1]

View source ↗

Summary

A Phase I trial assessing the combination of TPI-287 and temozolomide in melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• TPI-287
• Temozolomide (Temozolomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 1 | Status: TERMINATED